Health
Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer
Johnson & Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. The combination demonstrated a safety profile consistent with docetaxel alone, with no new or unexpected safety signals observed. The regimen also showed clinically meaningful efficacy, including high rates of prostate-specif
About this update from Johnson & Johnson
[{"type":"text","content":"Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3","length":107,"tagName":"p"},{"type":"text","content":"Data highlight the potential of this first-in-class next-generation T-cell engager to expand the role of immunotherapy in prostate cancer","length":137,"tagName":"p"},{"type":"text","content":"RARITAN, N.J., Feb. 26, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. The combination demonstrated a safety profile consistent with docetaxel alone, with no new or unexpected safety signals observed. The regimen also showed clinically meaningful efficacy, including high rates of prostate-specific antigen (PSA) responses and sustained PSA reductions, supporting continued development and advancement into Phase 3 studies. The results were presented for the first time at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (Abstract #171).1","length":829,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Johnson & Johnson)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Johnson & Johnson)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":37,"url":"https://media.zenfs.com/en/prnewswire.com/f6c13e47c55b1b30082ae2cdc7f55cf9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jIgvao1bUyQtFqwMNBmckA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTY1O2NmPXdlYnA-/https://media.zenfs.com/en/prnewswire.com/f6c13e47c55b1b30082ae2cdc7f55cf9","width":400,"height":37}},"href":"https://mma.prnewswire.com/media/2333578/Johnson_and_Johnson_Logo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Pasritamig is designed to engage the immune system through a novel mechanism of action, binding CD3 on T cells and human kallikrein 2 (KLK2). KLK2 is a novel, highly specific prostate cancer target with minimal expression outside prostate tissue. By both activating and directing T cells to KLK2-expressing tumor cells, pasritamig enables targeted immune engagement. This differentiated, prostate-specific approach was intentionally built to focus immune activity on prostat...